Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;11(1):139-52.
doi: 10.1007/s13311-013-0231-4.

Treatment of dystonia

Mary Ann Thenganatt  1 , Joseph Jankovic
Affiliations
Review

Treatment of dystonia

Mary Ann Thenganatt et al. Neurotherapeutics. 2014 Jan.

Abstract

Selecting the appropriate treatment for dystonia begins with proper classification of disease based on age, distribution, and underlying etiology. The therapies available for dystonia include oral medications, botulinum toxin, and surgical procedures. Oral medications are generally reserved for generalized and segmental dystonia. Botulinum toxin revolutionized the treatment of focal dystonia when it was introduced for therapeutic purposes in the 1980s. Surgical procedures are available for medication-refractory dystonia, markedly affecting an individual's quality of life.

PubMed Disclaimer

References

    1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28:863–873. - PMC - PubMed
    1. Charlesworth G, Bhatia KP, Wood NW. The genetics of dystonia: new twists in an old tale. Brain. 2013;136:2017–2037. - PMC - PubMed
    1. Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. Mov Disord. 2011;26:1106–1126. - PubMed
    1. Pavese N. Dystonia: hopes for a better diagnosis and a treatment with long-lasting effect. Brain. 2013;136:694–695. - PubMed
    1. Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2013 (in press). - PMC - PubMed